Figure 1.
Progression-free survival in (A) patients with a BRCA mutation and (B) in patients with wild-type BRCA from the pivotal Phase II olaparib maintenance study in patients with platinum-sensitive relapsed serous ovarian cancer (Ledermann et al, 2012, 2014b). BRCAwt, wild type (includes patients with no known BRCA mutation or a mutation of unknown significance). Reprinted from Ledermann J et al (© 2014 with permission from Elsevier).